Zhongshan Chenxinghai Hospital recently obtained the first approval document for "Hong-Kong/Macao Medicine and Medical Equipment One-way Permit" in Guangdong, which allows the import and clinical use of the new oral anticancer drug "Lorlatinib" in the hospital. This is the first time that Zhongshan has introduced an international new drug simultaneously with Hong Kong and Macao through this policy.

Lorlatinib is only third-generation ALK (Anaplastic Lymphoma Kinase) inhibitor in the world approved for marketing. It is suitable for ALK positive patients with advanced non-small cell lung cancer.

In August 2021, Zhongshan, Guangzhou, Shenzhen and Zhuhai became the first four cities to implement the "Hong-Kong/Macao Medicine and Medical Equipment One-way Permit" policy, and five hospitals including Zhongshan Chenxinghai Hospital (level-3 hospital) became the first designated medical institutions on the mainland.

By the end of 2021, Zhongshan Port was approved to import medicine from abroad, and the "Hong-Kong/Macao Medicine and Medical Equipment One-way Permit" policy was implemented in Zhongshan. These two advancements will help deepen the medical cooperation between Zhongshan and Hong Kong and Macao and contribute to the development of the biomedical industry.